Alseres Pharmaceuticals (Alseres Pharmaceuticals) Additional Paid-In Capital : $188.65 Mil(As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals Additional Paid-In Capital?

Alseres Pharmaceuticals's quarterly additional paid-in capital declined from Dec. 2013 ($188.66 Mil) to Mar. 2014 ($188.66 Mil) but then stayed the same from Mar. 2014 ($188.66 Mil) to Jun. 2014 ($188.65 Mil).

Alseres Pharmaceuticals's annual additional paid-in capital increased from Dec. 2011 ($166.17 Mil) to Dec. 2012 ($171.98 Mil) and increased from Dec. 2012 ($171.98 Mil) to Dec. 2013 ($188.66 Mil).

Alseres Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Alseres Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alseres Pharmaceuticals Additional Paid-In Capital Chart

Alseres Pharmaceuticals Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Additional Paid-In Capital

Get a 7-Day Free Trial

146.91

146.61

166.17

171.98

188.66

Alseres Pharmaceuticals Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
Additional Paid-In Capital	Get a 7-Day Free Trial															171.97	171.96	188.66	188.66	188.65

Alseres Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Alseres Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466

Website

http://www.alseres.com

Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.

Executives

Mark Jerome Pykett	officer: President and COO	223A MAIN ST, BOXFORD MA 021921
Robert Langer	director	98 MONTVALE RD, NEWTON MA 02459
Peter G Savas	director, officer: Chief Executive Officer	110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston	director	C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr	officer: Exec VP of Fin & Admin & CFO	C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon	officer: Chief Financial Officer	1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck	director	P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines

From GuruFocus

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 05-15-2009

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-16-2009

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-14-2009